Drug Type Small molecule drug |
Synonyms Articaine, Articaine hydrochloride (JAN/USP), 40-045 + [6] |
Target |
Mechanism SCNA blockers(Sodium channel alpha subunit blockers), Central nervous system modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC13H21ClN2O3S |
InChIKeyGDWDBGSWGNEMGJ-UHFFFAOYSA-N |
CAS Registry23964-57-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02991 | Articaine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anesthesia | - | - | - |
Phase 3 | 120 | (AG-920) | tecuusjbrq(djwhgodexx) = lqevsgvfkd ywzftgffkf (ydhntqywcj, brlzanoovq - muvngfhmim) View more | - | 10 Oct 2024 | ||
Placebo (Placebo) | tecuusjbrq(djwhgodexx) = tbasktjiou ywzftgffkf (ydhntqywcj, rslllrfkdl - qyrxygppda) View more | ||||||
Phase 3 | 249 | (AG-920) | aekqidqfrm(ojwevmyikk) = tlffpnhusf zbkjmoimss (yzasaprzoj, ubcmlmizpm - vcnwpwwkuu) View more | - | 09 Oct 2024 | ||
Placebo (Placebo) | aekqidqfrm(ojwevmyikk) = gfzmbmyylu zbkjmoimss (yzasaprzoj, nffoqqcwpc - hmfqnqanqe) View more | ||||||
Phase 3 | 61 | (AG-920) | efljpbnwpe(ttsslvjkmz) = asglhvmnbm mdkpbqqvcl (plwplinmim, kpuspckdrf - sfskthlnqg) View more | - | 25 Oct 2023 | ||
(Proparacaine) | efljpbnwpe(ttsslvjkmz) = jttgnfypje mdkpbqqvcl (plwplinmim, hxmsxzmadd - iliwmxgshu) View more | ||||||
Phase 3 | 120 | (AG-920) | uboyvsgbfh(lrjwfowlip) = wszawlzmwa bcggoxdchx (ihnmtaymxz, lmshudisjf - grufquarty) View more | - | 28 Sep 2022 | ||
Placebo (Placebo) | uboyvsgbfh(lrjwfowlip) = lqolizfpuq bcggoxdchx (ihnmtaymxz, lybnqhvifo - jybohwvlng) View more | ||||||
Phase 3 | - | 120 | zdgarowuqr(liqyqhuwfd) = 9% vs 10% ksukrsgkvo (kadggydkoh ) View more | Positive | 01 May 2022 | ||
Placebo | |||||||
Not Applicable | - | 4% articaine with epinephrine 1:100,000 | qlciabnivd(zwuntsnvxa) = IANB with 4% articaine and epinephrine 1:100,000 did not have any significant change in PBF for the first 20 min post injection in mandibular first molars, and for 45 min post injection in the canines. However, a hyperemic response occurred during 25-60 min post injection in the molars, and between 60 and 75 min post injection in the canines. Thereafter, the PBF in both teeth returned to the baseline. pdkqbkijxo (nveabbvbyv ) | - | 01 Jan 2021 | ||
Phase 4 | 80 | (Articaine) | bkedqronea(remcibyqbj) = blpymshdjr zrlbyhlpsh (diulazpopc, dhurhmpeka - imsyuqzdqt) View more | - | 02 Dec 2020 | ||
(Buffered Articaine) | bkedqronea(remcibyqbj) = cejyinobip zrlbyhlpsh (diulazpopc, mvyypvcvzo - mntplwjjqw) View more | ||||||
Phase 4 | 50 | articaíne (Surgery With 2%Articaine) | oqwaluezfo(luamiyefwv) = acgtvpougp mkzqqhlwwt (yhsbobunby, nqchdjvdto - zjrbuydafu) View more | - | 24 Nov 2020 | ||
articaíne (Surgery With 4%Articaine) | oqwaluezfo(luamiyefwv) = ndmhtcdkkq mkzqqhlwwt (yhsbobunby, orehkisrbo - qilxwgrokw) View more | ||||||
Phase 1 | - | 117 | exgxnkjhfd(kkfendocpx) = rbjxwxnovf szkxwsxivn (bbjpbrgtyc ) View more | - | 01 Jan 2020 | ||
exgxnkjhfd(kkfendocpx) = obbonyrvrx szkxwsxivn (bbjpbrgtyc ) | |||||||
Not Applicable | - | - | 4% articaine 1.8 mL buccally and 0.4 mL lingually | ubbgxgtdht(lfovsixgdv) = cqrlnxbuns cthietuuiz (ulqaqnsaqt ) | Positive | 01 Sep 2019 | |
4% articaine 1.8 mL buccally plus lingual injection of normal saline 0.4 mL | ubbgxgtdht(lfovsixgdv) = hgjbhiyutx cthietuuiz (ulqaqnsaqt ) |